Agios Pharmaceuticals Stock Drops Below 200-Day Average

Analysts Debate Whether Investors Should Sell Shares

Feb. 26, 2026 at 10:22am

Got story updates? Submit your updates here. ›

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) fell below their 200-day moving average on Wednesday, sparking debate among analysts about whether investors should sell the stock. The biopharmaceutical company's stock price closed at $29.96, down from a 200-day average of $33.61.

Why it matters

Agios Pharmaceuticals is a prominent biotech firm focused on developing cancer and rare disease treatments. The stock's performance is closely watched by investors, as it can signal broader trends in the pharmaceutical industry.

The details

Several equity research analysts have issued reports on Agios Pharmaceuticals in recent months. Wall Street Zen upgraded the stock from a 'sell' rating to 'hold', while Royal Bank of Canada downgraded it from 'outperform' to 'sector perform' and lowered the price target from $57 to $28. The Goldman Sachs Group also dropped its price objective from $40 to $25 and maintained a 'neutral' rating.

  • Agios Pharmaceuticals' stock price crossed below its 200-day moving average on Wednesday, February 26, 2026.
  • In November 2025, Royal Bank of Canada downgraded the stock and lowered its price target.
  • In December 2025, JPMorgan Chase & Co. lifted its price target on Agios Pharmaceuticals from $20 to $25 and maintained a 'neutral' rating.

The players

Agios Pharmaceuticals, Inc.

A biopharmaceutical company focused on developing cancer and rare disease treatments, headquartered in Cambridge, Massachusetts.

Wall Street Zen

An equity research firm that upgraded Agios Pharmaceuticals' stock rating from 'sell' to 'hold'.

Royal Bank of Canada

An investment bank that downgraded Agios Pharmaceuticals' stock from 'outperform' to 'sector perform' and lowered its price target.

The Goldman Sachs Group

An investment bank that dropped its price objective for Agios Pharmaceuticals from $40 to $25 and maintained a 'neutral' rating.

JPMorgan Chase & Co.

An investment bank that lifted its price target on Agios Pharmaceuticals from $20 to $25 and maintained a 'neutral' rating.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

The takeaway

Agios Pharmaceuticals' stock performance is closely watched by investors as an indicator of broader trends in the pharmaceutical industry. The company's recent stock price drop below its 200-day moving average has sparked debate among analysts about whether investors should sell their shares.